US healthcare giant Abbott has renamed the branded drugs part of its business

US healthcare giant Abbott has renamed the branded drugs part of its business following its decision to split that part from the medical devices part - creating two separate organisations. The new pharma company, to be launched by the end of 2012, will be called AbbVie, while the medical devices company - which will include the generic drugs and food supplements portfolio - will inherit the existing Abbott name. Richard Gonzalez, currently executive vice president for global pharmaceuticals, will become chief executive and chair of AbbVie.